HPV infection and carcinogenesis in the upper aero-digestive tract
Article Sidebar
Main Article Content
- Human papillomavirus
- Carcinogenesis
- Squamous cell carcinomas
- The upper aero-digestive tract
Parkin DM. The global health burden of infection-associatedcancers in the year 2002. Int J Cancer. 2006; 118: 3030-44.2.Mueller NE, Birmann B, Parsonnet J, Schiffman M, Stuver S.Infectious agents. In: Schottenfeld D, Fraumeni JF Jr, (eds.).Cancer epidemiology and prevention. 3rd ed. New York:Oxford University Press; 2005.3.D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C,Koch WM, et al. Case-control study of human papilloma virusand oropharyngeal cancer. N E n g l J M e d . 2007; 356: 1944-56.4.zur Hausen H. Papillomaviruses and cancer: from basic studiesto clinical application. Nat Rev Cancer. 2002; 2: 342-50.5.de Villiers EM, Fauquet C, Broker TR, Bernard HU, zurHausen H. Classification of papillomaviruses. Virology. 2004;324: 17-27.6.Van Ranst M, Kaplan JB, Burk RD. Phylogenetic classificationof human papillomaviruses: correlation with clinical mani-festations. J Gen Virol. 1992; 73: 2653-60.7.Muñoz N, Bosch FX, de Sanjosé S, Herrero R, CastellsaguéX, Shah KV, et al. Epidemiologic classification of humanpapillomavirus types associated with cervical cancer. N EnglJ Med. 2003; 348: 518-27.8.Yamada T, Manos MM, Peto J, Greer CE, Munoz N, BoschFX, et al. Human papillomavirus type 16 sequence variationin cervical cancers: a worldwide perspective. J Virol. 1997;71: 2463-72.9.Longworth MS, Laimins LA. Pathogenesis of humanpapillomaviruses in differentiating epithelia. Microbiol MolBiol Rev. 2004; 68: 362-72.10. Joyce JG, Tung JS, Przysiecki CT, Cook JC, Lehman ED,Sands JA, et al. The L1 major capsid protein of humanpapillomavirus type 11 recombinant virus-like particlesinteracts with heparin and cell-surface glycosaminoglycanson human keratinocytes. J Biol Chem. 1999; 274: 5810-22.11. Yoon CS, Kim KD, Park SN, Cheong SW. alpha (6) Integrinis the main receptor of human papillomavirus type 16 VLP.Biochem Biophys Res Commun. 2001; 283: 668-73.12. Doorbar J. The papillomavirus life cycle. J Clin Virol. 2005;32: S7-15.13. Münger K, Baldwin A, Edwards KM, Hayakawa H, NguyenCL, Owens M, et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol. 2004; 78: 11451-60.14. Moscicki AB, Schiffman M, Kjaer S, Villa LL. Updating thenatural history of HPV and anogenital cancer. Vaccine. 2006;24: S42-51.15. Um SJ, Rhyu JW, Kim EJ, Jeon KC, Hwang ES, Park JS.Abrogation of IRF-1 response by high-risk HPV E7 protein invivo. Cancer Lett. 2002; 179: 205-12.16. Wentzensen N, Vinokurova S, von Knebel Doeberitz M.Systematic review of genomic integration sites of humanpapillomavirus genomes in epithelial dysplasia and invasivecancer of the female lower genital tract. Cancer Res. 2004; 64:3878-84.17. Pett M, Coleman NJ. Integration of high-risk humanpapillomavirus: a key event in cervical carcinogenesis? JPathol. 2007; 212: 356-67.
Colombia Médica Vol. 42 Nº 2, 2011 (Abril-Junio)18. Duensing S, Münger K. Mechanisms of genomic instability inhuman cancer: insights from studies with human papillomavirusoncoproteins. Int J Cancer. 2004; 109: 157-62.19. Duensing S, Münger K. Human papillomavirus type 16 E7oncoprotein can induce abnormal centrosome duplicationthrough a mechanism independent of inactivation ofretinoblastoma protein family members. J Virol. 2003; 77:12331-5.20. Duensing S, Münger K. The human papillomavirus type 16 E6and E7 oncoproteins independently induce numerical andstructural chromosome instability. Cancer Res. 2002; 62:7075-82.21. Muñoz N, Castellsagué X, de González AB, Gissmann L.HPV in the etiology of human cancer. Vaccine. 2006; 24: S1-S10.22. Stewart BW, Kleihues P (eds.). World Cancer Report. Lyon:IARC Press; 2003.23. Schwartz JL. Biomarkers and molecular epidemiology andchemoprevention of oral carcinogenesis. Crit Rev Oral BiolMed. 2000; 11: 92-122.24. Montesano R, Hollstein M, Hainaut P. Genetic alterations inesophageal cancer and their relevance to etiology andpathogenesis: a review. Int J Cancer. 1996; 69: 225-35.25. Mandard AM, Hainaut P, Hollstein M. Genetic steps in thedevelopment of squamous cell carcinoma of the esophagus.Mutat Res. 2000; 462: 335-42.26. Ruesga MT, Acha-Sagredo A, Rodríguez MJ, AguirregaviriaJI, Videgain J, Rodríguez C, et al. p16(INK4a) promoterhypermethylation in oral scrapings of oral squamous cellcarcinoma risk patients. Cancer Lett.2007; 250: 140-5.27. Guha N, Boffetta P, Wünsch Filho V, Eluf Neto J, ShanginaO, Zaridze D, et al. Oral health and risk of squamous cellcarcinoma of the head and neck and esophagus: results of twomulticentric case-control studies. Am J Epidemiol. 2007; 166:1159-73.28. Yokoyama A, Muramatsu T, Ohmori T, Yokoyama T, OkuyamaK, Takahashi H, et al. Alcohol-related cancers and aldehydedehydrogenase-2 in Japanese alcoholics. Carcinogenesis.1998; 19: 1383-7.29. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, ElGhissassi F. WHO International Agency for Research onCancer. Carcinogenicity of human papillomaviruses. LancetOncol. 2005; 6: 204.30. Gillison ML, Shah KV. Role of mucosal human papillomavirusin nongenital cancers. J Natl Cancer Inst Monogr. 2003; 31:57-65.31. Castillo A, Aguayo F, Koriyama C, Torres M, Carrascal E,Corvalan A, et al. Human papillomavirus in esophagealsquamous cell carcinoma in Colombia and Chile. World JGastroenterol. 2006; 12: 6188-92.32. Shuyama K, Castillo A, Aguayo F, Sun Q, Khan N, KoriyamaC, et al. Human papillomavirus in high- and low-risk areas ofesophageal squamous cell carcinoma in China. Br J Cancer.2007; 96: 1554-9.33. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Humanpapillomavirus types in head and neck squamous cellcarcinomas worldwide: a systematic review. Cancer EpidemiolBiomarkers Prev. 2005;14:467-75.34. Miller CS, Johnstone BM. Human papillomavirus as a riskfactor for oral squamous cell carcinoma: a meta-analysis,1982-1997. Oral Surg Oral Med Oral Pathol Oral RadiolEndod. 2001; 91: 622-35.35. Maden C, Beckmann AM, Thomas DB, McKnight B, ShermanKJ, Ashley RL, et al. Human papilloma viruses, herpessimplex viruses, and the risk of oral cancer in men. Am JEpidemiol. 1992; 135: 1093-102.36. D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C,Koch WM, et al. Case-control study of human papillomavirusand oropharyngeal cancer. N E n g l J M e d . 2007; 356: 1944-56.37. Smith EM, Ritchie JM, Summersgill KF, Hoffman HT, WangDH, Haugen TH, Turek LP. Human papillomavirus in oralexfoliated cells and risk of head and neck cancer. J NatlCancer Inst. 2004; 96: 449-55.38. Herrero R, Castellsagué X, Pawlita M, Lissowska J, Kee F,Balaram P, et al. Human papillomavirus and oral cancer: theInternational Agency for Research on Cancer multicenterstudy. J Natl Cancer Inst. 2003; 95: 1772-83.39. Syrjanen KJ. HPV infections and esophageal cancer. J ClinPathol. 2002; 55: 721-8.40. Bjorge T, Hakulinen T, Engeland A, Jellum E, Koskela P,Lehtinen M, et al. A prospective, seroepidemiological studyof the role of human papillomavirus in esophageal cancer inNorway. Cancer Res. 1997; 57: 3989-92.41. Han C, Qiao G, Hubbert NL, Li L, Sun C, Wang Y, et al.Serologic association between human papillomavirus type 16infection and esophageal cancer in Shaanxi Province, China.J Natl Cancer Inst. 1996; 88: 1467-71.42. Van Doornum GJ, Korse CM, Buning-Kager JC, Bonfrer JM,Horenblas S, Taal BG, e t a l . Reactivity to human papillomavirustype 16 L1 virus-like particles in sera from patients withgenital cancer and patients with carcinomas at five differentextragenital sites. Br J Cancer. 2003; 88: 1095-100.43. Kamangar F, Qiao YL, Schiller JT, Dawsey SM, Fears T, SunXD, et al. Human papillomavirus serology and the risk ofesophageal and gastric cancers: Results from a cohort in ahigh-risk region in China. Int J Cancer. 2006; 119: 579-84.44. Gillison ML. HPV and prognosis for patients with oropharynxcancer. Eur J Cancer. 2009; 45: 383-5.45. Gillison ML. Human papillomavirus-related diseases:oropharynx cancers and potential implications for adolescentHPV vaccination. J Adolesc Health. 2008; 43: S52-60.46. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI,Nguyen-Tân PF, et al. Human papillomavirus and survival ofpatients with oropharyngeal cancer. N Engl J Med. 2010; 363:24-35.47. Scardina GA, Pisano T, Messina P. Oral and cervical lesionsassociated with human papillomavirus. Recenti Prog Med.2009; 100: 261-6.48. Rintala M, Grenman S, Puranen M, Syrjanen S. Naturalhistory of oral papillomavirus infections in spouses: aprospective Finnish HPV Family Study. J Clin Virol. 2006;35: 89-94.49. Hemminki K, Dong C, Frisch M. Tonsillar and other upperaerodigestive tract cancers among cervical cancer patients and
Colombia Médica Vol. 42 Nº 2, 2011 (Abril-Junio)their husbands. Eur J Cancer Prev. 2000; 9: 433-7.50. Puranen M, Yliskoski M, Saarikoski S, Syrjänen K, SyrjänenS. Vertical transmission of human papillomavirus from infectedmothers to their newborn babies and persistence of the virusin childhood. Am J Obstet Gynecol. 1996; 174: 694-9.51. Tsantoulis PK, Kastrinakis NG, Tourvas AD, Laskaris G,Gorgoulis VG. Advances in the biology of oral cancer. OralOncol. 2007; 43: 523-34.52. Oda D, Bigler L, Mao EJ, Disteche CM. Chromosomalabnormalities in HPV-16-immortalized oral epithelial cells.Carcinogenesis. 1996; 17: 2003-8.53. Park NH, Gujuluva CN, Baek JH, Cherrick HM, Shin KH,Min BM. Combined oral carcinogenicity of HPV-16 andbenzo(a)pyrene: an in vitro multistep carcinogenesis model.Oncogene. 1995; 10: 2145-53.54. De Roda Husman AM, Walboomers JM, van den Brule AJ,Meijer CJ, Snijders PJ. The use of general primers GP5 andGP6 elongated at their 3’ ends with adjacent highly conservedsequences improves human papillomavirus detection by PCR.J Gen Virol. 1995; 76: 1057-62.55. Kleter, B, Van Doorn LJ, Schrauwen L, Molijn A, SastrowijotoS, Schegget J ter, et al. Development and clinical evaluationof a highly sensitive PCR-reverse hybridization line probeassay for detection and identification of anogenital humanpapillomavirus. J Clin Microbiol. 1999; 37: 2508-17.56. Peitsaro P, Johansson B, Syrjanen S. Integrated humanpapillomavirus type 16 is frequently found in cervical cancerprecursors as demonstrated by a novel quantitative real-timePCR technique. J Clin Microbiol. 2002; 40: 886-91.57. Clavel C, Masure M, Putaud I, Thomas K, Bory JP, Gabriel R,et al. Hybrid capture II, a new sensitive test for humanpapillomavirus detection. Comparison with hybrid capture Iand PCR results in cervical lesions. J Clin Pathol. 1998; 51:737-40.58. Garland SM, Smith JS. Human papillomavirus vaccines:current status and future prospects. Drugs. 2010; 70: 1079-98.59. Allen JD, Coronado GD, Williams RS, Glenn B, Escoffery C,Fernandez M, et al. A systematic review of measures used instudies of human papillomavirus (HPV) vaccine acceptability.Vaccine. 2010; 28: 4027-37.60. Lin K, Doolan K, Hung CF, Wu TC. Perspectives for preventiveand therapeutic HPV vaccines. J Formos Med Assoc. 2010;109: 4-24
Downloads
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The copy rights of the articles published in Colombia Médica belong to the Universidad del Valle. The contents of the articles that appear in the Journal are exclusively the responsibility of the authors and do not necessarily reflect the opinions of the Editorial Committee of the Journal. It is allowed to reproduce the material published in Colombia Médica without prior authorization for non-commercial use